Sino Biopharmaceutical 

$0.7010
44
-$0.04-5.01% Wednesday 20:00

Statistics

Day High
0.6509
Day Low
0.6509
52W High
1.24
52W Low
0.593
Volume
1,000
Avg. Volume
733
Mkt Cap
13.15B
P/E Ratio
31.85
Dividend Yield
2.55%
Dividend
0.02

Upcoming

Dividends

2.55%Dividend Yield
Sep 26
$0.01
Jul 26
$0.01
Sep 25
$0.01
Jul 25
$0.01
Oct 24
$0.00
10Y Growth
10.48%
5Y Growth
4.43%
3Y Growth
-5.8%
1Y Growth
42.95%

Earnings

19AugExpected
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0
0.07
0.15
0.22
Expected EPS
0.13847930712
Actual EPS
0.2196051012078

Financials

7.21%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.49BRevenue
323.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SBMFF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.94B
Zai Lab Limited is involved in the discovery, development, and commercialization of innovative healthcare products, directly competing with Sino Biopharmaceutical's diverse portfolio in the Chinese market.
HUTCHMED (China) Limited
HCM
Mkt Cap2.45B
Hutchison China MediTech Limited, operating in the biopharmaceutical sector, focuses on oncology and immunology, which are also primary areas of focus for Sino Biopharmaceutical, making them direct competitors.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, competes globally, including in China, in areas such as oncology, where Sino Biopharmaceutical also has significant investments.
Sanofi
SNY
Mkt Cap106.01B
Sanofi operates globally in the pharmaceutical sector, including China, and its activities in areas like immunology and oncology make it a competitor to Sino Biopharmaceutical.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is a global pharmaceutical corporation with a broad product portfolio that includes treatments in areas where Sino Biopharmaceutical is active, such as oncology, making them competitors.
Novartis
NVS
Mkt Cap304.1B
Novartis AG, a global healthcare company, competes in various therapeutic areas including those that Sino Biopharmaceutical targets, such as oncology and immunology.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. is a global healthcare company that develops pharmaceuticals in key areas like oncology, directly competing with Sino Biopharmaceutical's product range.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC, a global biopharmaceutical company, competes in the development of medicines in oncology, cardiovascular, renal, metabolism, and respiratory diseases, areas that overlap with Sino Biopharmaceutical's interests.

About

Sino Biopharmaceutical Limited operates as a leading investment holding entity and a research and development-focused pharmaceutical conglomerate, primarily active within the People's Republic of China. Its business activities are organized into three primary divisions: Modernised Chinese Medicines and Chemical Medicines, Investment initiatives, and other miscellaneous operations. The company offers a comprehensive range of pharmaceutical products spanning various therapeutic areas. This portfolio includes oncology medications like Qingkeshu, Anxian, Yinishu, Genike, Anyue capsules, and Leweixin injections; cardio-cerebral vascular drugs such as Kaina and Anrixin tablets; and treatments for hepatitis, including Tianqingganmei injections and Tianqingganping enteric capsules. It also produces orthopedic medicines like Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medications; parenteral nutritious solutions such as Xinhaineng and Fenghaina injections; and other pharmaceuticals, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. Furthermore, its advanced drug offerings feature specific products like Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond its core pharmaceutical manufacturing, Sino Biopharmaceutical engages in a diverse set of related healthcare and commercial ventures. These encompass managing properties; the retail and distribution of pharmaceutical goods; providing optometry services and selling ophthalmic products; operating hospitals; and offering medical management, health information consultancy, and bio-tech transfer and advisory services. The company also manufactures and markets health food, performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical eyewear, and is involved in the research, development, and sale of medical devices and active pharmaceutical ingredients. The company was established in 2000 and has its corporate headquarters situated in Wan Chai, Hong Kong.
Show more...
CEO
S. Y. Tse
Employees
21435
Country
Cayman Islands
ISIN
KYG8167W1380
WKN
000A0CBDJ

Listings

0 Comments

Share your thoughts

FAQ

What is Sino Biopharmaceutical stock price today?
The current price of SBMFF is $0.70 USD — it has decreased by -5.01% in the past 24 hours. Watch Sino Biopharmaceutical stock price performance more closely on the chart.
What is Sino Biopharmaceutical stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Sino Biopharmaceutical stocks are traded under the ticker SBMFF.
Is Sino Biopharmaceutical stock price growing?
SBMFF stock has risen by +7.7% compared to the previous week, the month change is a +14.92% rise, over the last year Sino Biopharmaceutical has showed a -43.47% decrease.
What is Sino Biopharmaceutical market cap?
Today Sino Biopharmaceutical has the market capitalization of 13.15B
When is the next Sino Biopharmaceutical earnings date?
Sino Biopharmaceutical is going to release the next earnings report on April 01, 2027.
What were Sino Biopharmaceutical earnings last quarter?
SBMFF earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.02 USD resulting in a +58.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sino Biopharmaceutical revenue for the last year?
Sino Biopharmaceutical revenue for the last year amounts to 4.49B USD.
What is Sino Biopharmaceutical net income for the last year?
SBMFF net income for the last year is 323.63M USD.
Does Sino Biopharmaceutical pay dividends?
Yes, SBMFF dividends are paid semi-annual. The last dividend per share was 0.01 USD. As of today, Dividend Yield (FWD)% is 2.55%.
How many employees does Sino Biopharmaceutical have?
As of September 11, 2026, the company has 21,435 employees.
In which sector is Sino Biopharmaceutical located?
Sino Biopharmaceutical operates in the Health & Wellness sector.
When did Sino Biopharmaceutical complete a stock split?
The last stock split for Sino Biopharmaceutical was on August 14, 2020 with a ratio of 1.5:1.
Where is Sino Biopharmaceutical headquartered?
Sino Biopharmaceutical is headquartered in Hong Kong, Cayman Islands.